Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3282219 | Clinical Gastroenterology and Hepatology | 2015 | 13 Pages |
Abstract
In phase 3 studies in Japan, lubiprostone increased the weekly average number of SBMs and increased the quality of life of patients with CIC. Clinical Trial Notification of the Japanese Regulatory Authorities: 20-3296 and 20-3300.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Shin Fukudo, Michio Hongo, Hiroshi Kaneko, Masahiro Takano, Ryuji Ueno,